Novo Nordisk, Eli Lilly Cut GLP-1 Drug Prices

Novo Nordisks stock dips after Trump administrations announcement to reduce prices of GLP-one drugs, used for diabetes and obesity, by up to 40%. The pharmaceutical giant commits to investing an extra $10 billion in the US. New pricing for Medicare and Medicaid beneficiaries set to take effect in 2026, with all future drug launches following a most favored nation pricing strategy.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.